-
1.发明授权Substituted cathechols as inhibitors of IL-4 and IL-5 for the treatment of bronchial asthma 有权取代的导管胆固醇作为IL-4和IL-5的抑制剂用于治疗支气管哮喘公开(公告)号：US09302967B2
公开(公告)日：2016-04-05
申请号：US14110869
申请日：2012-04-11
Applicant: Santu Bandyopadhyay , Balaram Ghosh , Parasuraman Jaisankar , Bikas Chandra Pal , Siddhartha Roy , Bholanath Paul , Arjun Ram , Ulaganathan Mabalirajan , Nahid Ali , Arun Bandopadhyay , Aditya Konar , Jayashree Bagchi Chakraborty , Indrani Choudhury Mukherjee , Jaydeep Chaudhuri , Sanjit Kumar Mahato , Anirban Manna , Roma Sinha , Pradyot Bhattacharya , Jayaraman Vinayagam , Deba Prasad Jana , Sushovan Chowdhury
Inventor： Santu Bandyopadhyay , Balaram Ghosh , Parasuraman Jaisankar , Bikas Chandra Pal , Siddhartha Roy , Bholanath Paul , Arjun Ram , Ulaganathan Mabalirajan , Nahid Ali , Arun Bandopadhyay , Aditya Konar , Jayashree Bagchi Chakraborty , Indrani Choudhury Mukherjee , Jaydeep Chaudhuri , Sanjit Kumar Mahato , Anirban Manna , Roma Sinha , Pradyot Bhattacharya , Jayaraman Vinayagam , Deba Prasad Jana , Sushovan Chowdhury
IPC: A61K31/14 , A61K31/05 , C07C39/19 , A61K31/15 , A61K31/215 , A61K31/277 , A61K31/36 , C07C69/017 , C07C69/732 , C07C251/40 , C07C251/66 , C07C255/36 , C07D317/50
CPC classification number: C07C39/19 , A61K31/05 , A61K31/15 , A61K31/215 , A61K31/277 , A61K31/36 , C07C69/017 , C07C69/732 , C07C251/40 , C07C251/66 , C07C255/36 , C07D317/50
Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
Abstract translation: 本发明涉及通过抑制IL-4或IL-5途径抑制来治疗支气管哮喘的通式1的化合物。 本发明还涉及通式1化合物通过抑制IL-4或IL-5途径治疗支气管的用途。 本发明还涉及通过口服，鼻内，途径或通过吸入需要的哺乳动物施用化合物或所述组合物来抑制IL-4或IL-5途径来治疗哮喘的方法。 通式1的化合物可用于减少血管周围和支气管炎。
-
2.发明申请公开(公告)号：US20050282892A1
公开(公告)日：2005-12-22
申请号：US11174545
申请日：2005-07-06
Applicant: Santu Bandyopadhyay , Bikas Pal , Samir Bhattacharyay , Swapan Mondal , Chhabinath Mandal , Aditya Konar , Keshab Roy , Tanusree Biswas , Gautam Bandyopadhyay
Inventor： Santu Bandyopadhyay , Bikas Pal , Samir Bhattacharyay , Swapan Mondal , Chhabinath Mandal , Aditya Konar , Keshab Roy , Tanusree Biswas , Gautam Bandyopadhyay
IPC: A61K31/192 , A61K31/215 , A61K31/216 , A61K31/235 , A61K31/70 , A61K31/716 , A61K45/06
CPC classification number: A61K31/235 , A61K31/192 , A61K31/215 , A61K31/216 , A61K31/70 , A61K31/716 , A61K45/06 , A61K2300/00
Abstract: This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
Abstract translation: 本发明涉及一种用于治疗慢性骨髓性白血病的药物组合物，其中Bcr-Abl激酶在动物和人体中组成型表达，并且通过包含有效量的类似物和/或盐类型的组合物的组合物治疗慢性骨髓性白血病（CML） 绿原酸。 类似物优选由绿原酸或其类似物制备的氯酸钠（Na-Chl）或钾盐或铵盐。
-
公开(公告)号：US08519154B2
公开(公告)日：2013-08-27
申请号：US13365979
申请日：2012-02-03
Applicant: Sibabrata Mukhopadhyay , Mumu Chakraborty , Tulika Mukherjee , Arun Bandyopadhyay , Dipak Kar , Tanima Banerjee , Aditya Konar , Debaprasad Jana , Siddhartha Roy , Santu Bandyopadhyay , Balram Ghosh , Mabalirajan Ulaganathan , Rakesh Kamal Johri , Subhash Chander Sharma , Gurdarshan Singh , Bholanath Paul , Vasanta Madhava Sharma Gangavaram , Jhillu Singh Yadav , Radha Krishna Palakodety
Inventor： Sibabrata Mukhopadhyay , Mumu Chakraborty , Tulika Mukherjee , Arun Bandyopadhyay , Dipak Kar , Tanima Banerjee , Aditya Konar , Debaprasad Jana , Siddhartha Roy , Santu Bandyopadhyay , Balram Ghosh , Mabalirajan Ulaganathan , Rakesh Kamal Johri , Subhash Chander Sharma , Gurdarshan Singh , Bholanath Paul , Vasanta Madhava Sharma Gangavaram , Jhillu Singh Yadav , Radha Krishna Palakodety
IPC: C07D209/82 , C07D209/88 , A61K31/403
CPC classification number: C07D209/86 , A61K31/404
Abstract: The present invention relates to a method for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD) comprising administering to the patient suffering from asthma and COPD an effective dose of carbazole derivatives or salt thereof, optionally along with pharmaceutically acceptable excipients.Structural formula of the compounds of general formula 1 useful as phosphodiesterase-4 (PDE-4) enzyme inhibitors, inhibitor for signalling molecule for the treatment of asthma and asthma related diseases is given below: wherein R1=H or OCH3; R2═CH3 or CHO; R3═H or OCH3; R4═H or OCH3 Herbal route for the isolation of compound of general formula 1 from the bark of plant Murraya Koenigii and chemical route for the preparation of such compounds from basic compounds such as vanillin is also reported.
Abstract translation: 本发明涉及一种治疗支气管哮喘和慢性阻塞性肺疾病（COPD）的方法，其包括向患有哮喘和COPD的患者施用有效剂量的咔唑衍生物或其盐，任选地与药学上可接受的赋形剂。 用作磷酸二酯酶-4（PDE-4）酶抑制剂的通式1化合物的结构式，用于治疗哮喘和哮喘相关疾病的信号分子抑制剂如下：其中R1 = H或OCH3; R2 = CH3或CHO; R3 = H或OCH3; R4 = H或OCH3用于从植物Murraya Koenigii的树皮中分离通式1的化合物的草药路线以及用于从碱性化合物如香草醛制备这些化合物的化学途径也被报道。
-
公开(公告)号：US20120202868A1
公开(公告)日：2012-08-09
申请号：US13365979
申请日：2012-02-03
Applicant: Sibabrata MUKHOPADHYAY , Mumu CHAKRABORTY , Tulika MUKHERJEE , Arun BANDYOPADHYAY , Dipak KAR , Tanima BANERJEE , Aditya KONAR , Debaprasad JANA , Siddhartha ROY , Santu BANDYOPADHYAY , Balram GHOSH , Mabalirajan ULAGANATHAN , Rakesh Kamal JOHRI , Subhash Chander SHARMA , Gurdarshan SINGH , Bholanath PAUL , Vasanta Madhava Sharma GANGAVARAM , Jhillu Singh YADAV , Radha Krishna PALAKODETY
Inventor： Sibabrata MUKHOPADHYAY , Mumu CHAKRABORTY , Tulika MUKHERJEE , Arun BANDYOPADHYAY , Dipak KAR , Tanima BANERJEE , Aditya KONAR , Debaprasad JANA , Siddhartha ROY , Santu BANDYOPADHYAY , Balram GHOSH , Mabalirajan ULAGANATHAN , Rakesh Kamal JOHRI , Subhash Chander SHARMA , Gurdarshan SINGH , Bholanath PAUL , Vasanta Madhava Sharma GANGAVARAM , Jhillu Singh YADAV , Radha Krishna PALAKODETY
IPC: A61K31/403 , A61P11/06 , C07D209/86
CPC classification number: C07D209/86 , A61K31/404
Abstract: The present invention relates to a method for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD) comprising administering to the patient suffering from asthama and COPD an effective dose of carbazole derivatives or salt thereof, optionally along with pharmaceutically acceptable excipients. Structural formula of the compounds of general formula 1 useful as phosphodiesterase-4 (PDE-4) enzyme inhibitors, inhibitor for signalling molecule for the treatment of asthma and asthma related diseases is given below: wherein R1=H or OCH3; R2═CH3 or CHO; R3═H or OCH3; R4═H or OCH3 Herbal route for the isolation of compound of general formula 1 from the bark of plant Murraya Koenigii and chemical route for the preparation of such compounds from basic compounds such as vanillin is also reported.
Abstract translation: 本发明涉及一种治疗支气管哮喘和慢性阻塞性肺疾病（COPD）的方法，其包括向患有哮喘和COPD的患者施用有效剂量的咔唑衍生物或其盐，任选地与药学上可接受的赋形剂。 用作磷酸二酯酶-4（PDE-4）酶抑制剂的通式1化合物的结构式，用于治疗哮喘和哮喘相关疾病的信号分子抑制剂如下：其中R1 = H或OCH3; R2 = CH3或CHO; R3 = H或OCH3; R4 = H或OCH3用于从植物Murraya Koenigii的树皮中分离通式1的化合物的草药途径以及用于从碱性化合物如香草醛制备这些化合物的化学途径也被报道。
-
5.发明授权Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant Pueraria tuberosa 失效草药提取物和化合物lupinoside及其类似物作为来自植物葛根结节的抗糖尿病II型药物公开(公告)号：US07276258B2
公开(公告)日：2007-10-02
申请号：US10809645
申请日：2004-03-25
Applicant: Debleena Dey , Swapan Kumar Mandal , Mohua Mukherjee , Bikash Chandra Pal , Tanushree Biswas , Malabika Datta , Sib Sankar Roy , Arun Bandyopadhyay , Samir Bhattacharya , Bir Bhanu Giri , Santu Bandopadhyay , Aditya Konar
Inventor： Debleena Dey , Swapan Kumar Mandal , Mohua Mukherjee , Bikash Chandra Pal , Tanushree Biswas , Malabika Datta , Sib Sankar Roy , Arun Bandyopadhyay , Samir Bhattacharya , Bir Bhanu Giri , Santu Bandopadhyay , Aditya Konar
CPC classification number: A61K31/70 , A61K36/488 , Y10S514/866
Abstract: The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA4), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.
Abstract translation: 本发明涉及预防和/或治疗糖尿病2型的方法，还涉及增加Glut4磷酸化和Glut4易位到靶细胞膜以增强信号转导途径中的胰岛素信号的方法; 此外，本发明涉及一种简单且便宜的获得提取物的方法，其后选择性地，其活性正丁醇级分和活性分子Lupinoside PA（LPA 4 S）可用于预防和/或治疗糖尿病2型 ; 最后是其药物组合物。
-
Patent Agency Ranking
6.发明授权Inhibitors of phosphatidylinositol-3-kinase (PI3) and inducers of nitric oxide (NO) 有权磷脂酰肌醇-3-激酶（PI3）和一氧化氮（NO）诱导剂的抑制剂公开(公告)号：US09290473B2
公开(公告)日：2016-03-22
申请号：US13144263
申请日：2010-01-12
Applicant: Santu Bandyopadhyay , Bikas Chandra Pal , Jaisankar Parasuraman , Siddhartha Roy , Jayashree Bagchi Chakrabotry , Indrani Choudhury Mukherjee , Sanjit Kumar Mahato , Aditya Konar , Srabanti Rakshit , Labanya Mandal , Dipyaman Ganguly , Kausik Paul , Anirban Manna , Jayaraman Vinayagam , Churala Pal
Inventor： Santu Bandyopadhyay , Bikas Chandra Pal , Jaisankar Parasuraman , Siddhartha Roy , Jayashree Bagchi Chakrabotry , Indrani Choudhury Mukherjee , Sanjit Kumar Mahato , Aditya Konar , Srabanti Rakshit , Labanya Mandal , Dipyaman Ganguly , Kausik Paul , Anirban Manna , Jayaraman Vinayagam , Churala Pal
IPC: A61K31/36 , C07C215/54 , C07C255/33 , C07C39/10 , C07D317/06 , C07C251/40 , C07C251/66 , C07C255/36 , C07C255/38
CPC classification number: C07D317/06 , C07C251/40 , C07C251/66 , C07C255/36 , C07C255/38
Abstract: The present invention relates to compounds of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention also relates to the use of compound of general formula 1 for the treatment of malignancy by inhibition of PI3-Akt pathway and or induction of NO. The present invention further relates to a method of treating malignancy by inhibition of PI3-Akt pathway and or induction of NO by administration of compound or said composition to a mammal in need thereof.
Abstract translation: 本发明涉及用于通过抑制PI3-Akt途径和或诱导NO来治疗恶性肿瘤的通式1的化合物。 本发明还涉及通式1的化合物用于通过抑制PI3-Akt途径和或诱导NO而治疗恶性肿瘤的用途。 本发明还涉及通过向有需要的哺乳动物施用化合物或所述组合物来抑制PI3-Akt通路和/或诱导NO治疗恶性肿瘤的方法。
-
7.发明申请SUBSTITUTED CATHECHOLS AS INHIBITORS OF IL-4 AND IL-5 FOR THE TREATMENT BRONCHIAL ASTHMA 审中-公开作为IL-4和IL-5的抑制剂作为治疗性胆碱性哮喘的替代物公开(公告)号：US20140135393A1
公开(公告)日：2014-05-15
申请号：US14110869
申请日：2012-04-11
Applicant: Santu Bandyopadhyay , Balaram Ghosh , Parasuraman Jaisankar , Bikas Chandra Pal , Siddhartha Roy , Balaram Ghosh , Parasuraman Jaisankar , Bikas Pal , Nahid Ali , Siddhartha Roy , Bholanath Paul , Arjun Ram , Siddhartha Roy , Bholanath Paul , Arjun Ram , Ulaganathan Mabalirajan , Nahid Ali , Arun Bandopadhyay , Aditya Konar , Jayashree Bagchi Chakraborty , Indrani Chowdhury Mukherjee , Jaydeep Chaudhuri , Sanjit Kumar Mahato , Anirban Manna , Roma Sinha , Prayot Bhattacharya , Jayaraman Vinayagam , Deba Prasad Jana , Sushovan Chowdhury
Inventor： Santu Bandyopadhyay , Balaram Ghosh , Parasuraman Jaisankar , Bikas Chandra Pal , Siddhartha Roy , Balaram Ghosh , Parasuraman Jaisankar , Bikas Pal , Nahid Ali , Siddhartha Roy , Bholanath Paul , Arjun Ram , Siddhartha Roy , Bholanath Paul , Arjun Ram , Ulaganathan Mabalirajan , Nahid Ali , Arun Bandopadhyay , Aditya Konar , Jayashree Bagchi Chakraborty , Indrani Chowdhury Mukherjee , Jaydeep Chaudhuri , Sanjit Kumar Mahato , Anirban Manna , Roma Sinha , Prayot Bhattacharya , Jayaraman Vinayagam , Deba Prasad Jana , Sushovan Chowdhury
IPC: C07C39/19 , C07C251/40 , C07D317/50 , C07C255/36 , C07C69/732 , C07C69/017 , C07C251/66
CPC classification number: C07C39/19 , A61K31/05 , A61K31/15 , A61K31/215 , A61K31/277 , A61K31/36 , C07C69/017 , C07C69/732 , C07C251/40 , C07C251/66 , C07C255/36 , C07D317/50
Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.
Abstract translation: 本发明涉及通过抑制IL-4或IL-5途径抑制来治疗支气管哮喘的通式1的化合物。 本发明还涉及通式1化合物通过抑制IL-4或IL-5途径治疗支气管的用途。 本发明还涉及通过口服，鼻内，途径或通过吸入需要的哺乳动物施用化合物或所述组合物来抑制IL-4或IL-5途径来治疗哮喘的方法。 通式1的化合物可用于减少血管周围和支气管炎。
-
8.发明申请公开(公告)号：US20070161704A1
公开(公告)日：2007-07-12
申请号：US11640401
申请日：2006-12-18
Applicant: Santu Bandyopadhyay , Bikas Pal , Samir Bhattacharyay , Swapan Mondal , Chhabinath Mandal , Aditya Konar , Keshab Roy , Tanusree Biswas , Gautam Bandyopadhyay
Inventor： Santu Bandyopadhyay , Bikas Pal , Samir Bhattacharyay , Swapan Mondal , Chhabinath Mandal , Aditya Konar , Keshab Roy , Tanusree Biswas , Gautam Bandyopadhyay
IPC: A61K31/235
CPC classification number: A61K31/235 , A61K31/192 , A61K31/215 , A61K31/216 , A61K31/70 , A61K31/716 , A61K45/06 , A61K2300/00
Abstract: This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.
Abstract translation: 本发明涉及一种用于治疗慢性骨髓性白血病的药物组合物，其中Bcr-Abl激酶在动物和人体中组成型表达，并且通过包含有效量的类似物和/或盐类型的组合物的组合物治疗慢性骨髓性白血病（CML） 绿原酸。 类似物优选由绿原酸或其类似物制备的氯酸钠（Na-Chl）或钾盐或铵盐。
-
公开(公告)号：US09408888B2
公开(公告)日：2016-08-09
申请号：US13980701
申请日：2012-01-30
Applicant: Amlanjyoti Dhar , Shampa Mallick , Israr Ahmed , Aditya Konar , Santu Bandyopadhyay , Siddhartha Roy
Inventor： Amlanjyoti Dhar , Shampa Mallick , Israr Ahmed , Aditya Konar , Santu Bandyopadhyay , Siddhartha Roy
CPC classification number: A61K38/16 , A61K9/0019 , A61K38/10 , A61K45/06 , C07K14/00 , C07K14/47 , A61K2300/00
Abstract: The present invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.
Abstract translation: 本发明描述了针对S100B的新型二价螺旋约束肽，其是针对过表达S100B的癌症的有效抗癌药物。 靶向S100B的这种螺旋模拟物通过同时抑制关键生长途径（包括p53的激活）诱导过度表达钙结合蛋白S100B的癌细胞中的快速凋亡。
-
10.发明申请公开(公告)号：US20140155331A1
公开(公告)日：2014-06-05
申请号：US13980701
申请日：2012-01-30
Applicant: Amlanjyoti Dhar , Shampa Mallick , Israr Ahmed , Aditya Konar , Santu Bandyopadhyay , Siddhartha Roy
Inventor： Amlanjyoti Dhar , Shampa Mallick , Israr Ahmed , Aditya Konar , Santu Bandyopadhyay , Siddhartha Roy
CPC classification number: A61K38/16 , A61K9/0019 , A61K38/10 , A61K45/06 , C07K14/00 , C07K14/47 , A61K2300/00
Abstract: The present invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.
Abstract translation: 本发明描述了针对S100B的新型二价螺旋约束肽，其是针对过表达S100B的癌症的有效抗癌药物。 靶向S100B的这种螺旋模拟物通过同时抑制关键生长途径（包括p53的激活）诱导过度表达钙结合蛋白S100B的癌细胞中的快速凋亡。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.013 seconds)
